Introduction Dyslipidemia is a common public health problem in people living with human
immunodeficiency virus (HIV) who are receiving antiretroviral therapy and increases the risk …

Background. There is an increasing prevalence of cardiovascular diseases (CVDs) and risk
factors in HIV patients as the levels of AIDS‐related mortality and morbidity decrease …

Background Long-term use of antiretroviral therapy, especially dolutegravir and boosted-
atazanavir, raises concerns about cardiovascular disease. Thus, this study aimed to assess …

Nurses as a health professional has a significant role in primary health services in nurturing,
and also enabling the community to healthy behavior. Nurse students will become role …

Hypertension is a risk factor for end organ damage and death and is more common in
persons with HIV compared to the general population. Several mechanisms have been …

Background Understanding the burden of dyslipidemia and its associated factors among
adult people living with HIV on dolutegravir (DTG) based anti-retroviral therapy (ART) is …

Background Antiretroviral therapy-linked metabolic abnormalities have become a growing
concern among people living with HIV. There is limited data regarding the effects of …

Background Despite increasing morbidity and mortality from non-communicable diseases
(NCD) globally, health systems in low-and middle-income countries (LMICs) have limited …

Purpose This study aimed to assess the burden of metabolic syndrome among people living
with HIV (PLWH) on dolutegravir (DTG)-and efavirenz (EFV)-based regimens. Methods A …

Methods: In this cross-sectional explorative study, traditional CVD risk factors were
assessed, and 10-year Framingham and atherosclerotic cardiovascular disease (ASCVD) …